Navigation Links
Study shows positive findings in treating patients with advanced hepatitis C
Date:4/24/2008

MILAN, ITALY, April 24, 2008 The hepatitis C therapy peginterferon alfa-2b, when given as low-dose maintenance therapy, can prevent disease progression in certain patients who failed previous interferon-based hepatitis C therapies and have advanced liver disease, according to findings from a large, four-year study presented today at the 43rd annual meeting of the European Association for the Study of the Liver (EASL).

The study, called COPILOT (COlchicine versus Peg-Intron LOng-Term), showed that low-dose peginterferon alfa-2b was superior to colchicine in improving the disease-free survival of patients with cirrhosis and portal hypertension, especially in patients who stayed on treatment. In the study, more than 40 percent of patients had portal hypertension, a condition of high blood pressure in the major vessel going to the liver from the gastrointestinal tract and which often accompanies liver cirrhosis. However, peginterferon alfa-2b maintenance therapy was not superior to colchicine in patients overall.

These findings make a strong case for considering low-dose peginterferon alfa-2b as a maintenance therapy in patients with cirrhosis and portal hypertension who have failed hepatitis C eradication therapy, said principal investigator Nezam Afdhal, M.D., Chief of Hepatology at Beth Israel Deaconess Medical Center (BIDMC) and Associate Professor of Medicine at Harvard Medical School. While other interferon maintenance therapies have been studied in the past few years in previous interferon nonresponders, these findings show, for the first time, a clinical benefit in a specific population with advanced disease, he said.

Hepatitis C virus (HCV) infection is transmitted through exposure to infected blood and affects an estimated 4 million individuals in the United States. The current standard treatment, combination therapy with pegylated interferon plus ribavirin for 24 to 48 weeks, can eradicate the virus in about 50 percent of patients. Those who do not respond and have cirrhosis are at far greater risk for developing liver cancer or liver failure, so the development of treatment strategies for these nonresponders is a priority.

Conducted at approximately 40 sites in the United States, the COPILOT study compared weight-based low-dose peginterferon alfa-2b (subcutaneous injection of 0.5 mcg/kg/wk, one-third the dose used in standard HCV combination therapy) versus colchicine (0.6 mg orally, twice daily), an anti-inflammatory and antifibrotic medication, in 555 chronic hepatitis C patients with advanced liver fibrosis who previously failed interferon-based therapies. Patient baseline characteristics were well balanced between the two study arms. Over the four years of the randomized study, investigators monitored the patients to determine how many reached a primary endpoint, defined as death, liver transplant, hepatocellular carcinoma (liver cancer), variceal bleeding, or liver failure (increase in Child-Pugh-Turcotte [CPT] by 2 points with ascites, jaundice or encephalopathy). They analyzed their findings for all 555 patients, who received at least one dose of their assigned drug, in two ways: based on all events that occurred during the entire four years of the study, regardless of whether a patient was still taking their assigned drug or not (the intent-to-treat or ITT analysis), and based on only the events that occurred while patients were taking their assigned drug (the on drug analysis).

The investigators found a primary endpoint was reached by 17.8% (51/286) of patients in the peginterferon alfa-2b group versus 20.4% (55/269) in the colchicine group in the ITT analysis, and by 12.2% (35/286) and 16.0% (43/269) patients, respectively, in the on-drug analysis (treatment differences were not statistically significant). Among patients who had portal hypertension (42.3% and 48.0% of patients in the peginterferon alfa-2b and colchicine groups, respectively), peginterferon alfa-2b therapy resulted in significantly improved event-free survival in both the ITT and on-drug analyses (Wilcoxon p = 0.041 and 0.028, respectively). Further, variceal bleeding, a specific complication of portal hypertension, was almost abolished with peginterferon alfa-2b in both the ITT (10 vs. 1 patients) and the on-drug (10 vs. 0 patients) analyses. In the ITT analysis, hepatocellular carcinoma occurred in 7.7% and 5.9% of patients in the peginterferon alfa-2b and colchicine groups, respectively, a non-significant difference.

Overall, 49% of patients discontinued their medication before the end of the four-year study, with 36% due to failure to comply and 13% due to side effects. Peginterferon alfa-2b was generally well tolerated. Among patients who discontinued due to interferon side effects (17.1%, 49/286), the most common reason (45%, 22/49 patients) was general intolerance to interferon (e.g., due to flu-like symptoms, malaise, and other common interferon side effects).


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related medicine news :

1. Study finds racial disparities in smoking cessation treatment
2. Antipodean Pharmaceuticals Announces Results of Phase 2 Study of Lead Compound MitoQ(R)
3. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
4. Study finds that competency in colonoscopy requires experience with 150 cases or more
5. Study finds cisplatin less effective than standard treatment for patients with anal cancer
6. Potential viral therapy weapon for difficult cancers is safe and effective in study
7. Study: Counseling trauma victims causes secondary trauma
8. Rat study suggests why teens get hooked on cocaine more easily than adults
9. Study Shows Increased Out-of-Pocket Expenses May Negatively Influence Initiation of TNF Blocker Therapy
10. Teenage suicides: Study advocates greater family support
11. Cancer cells spread by releasing bubbles, according to an MUHC study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... Adolfson & Peterson Construction (AP) ... Ramsey County Medical Examiners Facility located in Saint Paul, Minn. A single story, ... scheduled to start in late 2017/early 2018. , Staffed by 20 full-time ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... its ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” ... plaintiff Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it ...
(Date:7/21/2017)... OR (PRWEB) , ... July 21, 2017 , ... ... recent weeks Nature’s Tears® EyeMist®, the signature product of her research center at ... with the world’s largest population and the greatest number of sufferers of blindness. ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... TransPixel Volume ... between two clips in the FCPX timeline. This effect isolates horizontal and vertical lines ... this package contains either a rotating or flipping animation and can be changed using ...
(Date:7/20/2017)... ... ... For individuals with extended hospital stays or who are residents of nursing ... specially designed to accommodate patients with a wide range of ailments or special needs, ... has invented the patent-pending PORTABLE ARM REST, a specially designed armrest that features many ...
Breaking Medicine News(10 mins):
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)...  Axium Pharmaceuticals Inc. is a pharmaceutical company aimed at utilizing ... dosage forms of existing biologically active molecule. ... Subveta oral ... emulsifying formula, which is designed to prevent precipitation of the ... will provide fast onset of action and is designed to ...
(Date:6/20/2017)... LAGUNA HILLS, Calif. , June 20, 2017 /PRNewswire/ ... validate the use of MMprofiler with SKY92, the company,s ... (MM). In a poster presentation at the 22 nd ... Madrid, Spain , SkylineDx researchers will ... elderly patients. In a separate e-poster ...
Breaking Medicine Technology: